Words by Josh Hardman.
***
We have barely kicked off 2025 and already a handful of ketamine-related news stories have emerged. In this ketamine-focused round-up, we explore:
- The British government is considering reclassifying ketamine to Class A, alongside drugs like cocaine and heroin, ostensibly due to rising illicit use and health concerns.
- Janssen’s esketamine nasal spray, Spravato, has become a blockbuster drug with over $1 billion in annual sales and now FDA approval as a monotherapy for treatment-resistant depression. But a recent meta-analysis questions its efficacy, particularly in addressing suicidality.
- Deep Dive: Mindbloom’s new at-home injectable ketamine program has sparked significant controversy within the psychedelics community, with critics raising safety, ethical, and regulatory concerns—while the company dismisses the backlash as industry-driven opposition and doubles down on its marketing efforts.
- DEA publishes its proposed telehealth registration scheme for entities looking to prescribe controlled substances remotely, which will have repercussions for at-home ketamine providers.
To continue reading, please log in or join Pα+…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
